-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
Since December 2019, the new type of coronavirus (SARS-CoV-2) that causes severe acute respiratory syndrome has triggered a global pandemic of COVID-19, which has infected more than 279 million people so far
On December 15, 2021, the team of Jianqing Xu/Xiaoyan Zhang of our hospital , the team of Professor Dongming Zhou of Tianjin Medical University, and the team of Professor Zhao Ping of the Second Military Medical University jointly published the title "A single vaccine protects against" in the Journal of Virology (JVI).
In order to be able to construct a vaccine against both the new coronavirus and influenza virus, the authors used the receptor binding domain (RBD) of the new coronavirus to fuse with the conserved stem region (HA2) of H7N9 hemagglutinin, and introduced human ferritin ( ferritin) to further improve its immunogenicity, and then the fusion immunogen (CoV/Flu) is expressed by chimpanzee adenovirus 68 (AdC68) (AdC68-CoV/Flu)
Data against influenza viruses show that the vaccine can induce a high level of antibody response against H7 in mice, and a strong antibody response against H3
In summary, AdC68-CoV/Flu can simultaneously provide protection against SARS-CoV-2 and influenza A viruses in mice, opening up new ideas for the development of broad-spectrum vaccines for respiratory diseases
Original link:
https://journals.